Roche, GSK outline head-to-head trial of Boniva, Fosamax

Roche and GlaxoSmithKline plan to mount a head-to-head trial to test their osteoporosis treatment Boniva against Merck's Fosamax. Researchers will enroll 1,900 women with postmenopausal osteoporosis. "This is a very important study because these two treatment regimens have never before been directly compared," said Felicia Cosman, M.D., medical director of the Clinical Research Center, Helen Hayes Hospital in West Haverstraw, New York. "This trial will measure each treatment's ability to increase bone mineral density, an accepted surrogate for determining the risk of fracture -- the most relevant consequence of postmenopausal osteoporosis."

- read this wire report from AFX for more